-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Infection prevention and immunity Recently, researchers investigated the role of Lactobacillus rhamnosus in the prevention of ventilator-associated pneumonia (VAP), other infections, and other clinically important results in the ICU ward
The study was carried out in 44 ICU centers in Canada, the United States, and Saudi Arabia, involving 2653 critically ill adult patients who are expected to require mechanical ventilation for at least 72 hours
The average age of the patients was 59.
VAP was found in 289 (21.
VAP and other infection risk differences between groups
VAP and other infection risk differences between groups VAP and other infection risk differences between groupsStudies believe that in critically ill patients who require mechanical ventilation in the ICU, receiving Lactobacillus rhamnosus treatment will not reduce the risk of ventilator-associated pneumonia
In critically ill patients requiring mechanical ventilation in the ICU, treatment with Lactobacillus rhamnosus does not reduce the risk of ventilator-associated pneumonia.
Original source:
Jennie Johnstone et al.
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients A Randomized Clinical Trial.
JAMA
Leave a message here
